When US tech stocks were crushed by the emergence of DeepSeek this week, already-cautious investors found one more reason to ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech ...

UiPath's share price may have dropped since IPO, but it remains a key AI winner for 2025 with high growth potential and a ...

Wedbush analyst Dan Ives has expressed skepticism over Chinese startup DeepSeek’s assertion of developing its low-cost AI ...

The government formally began its push to build a foundational AI model on Thursday. This and more in todays ETtech Morning ...

Safe-haven demand due to geopolitical uncertainties and concerns over global economic growth amid U.S. President Donald Trump ...

The Dow Jones rose Thursday on surprise weekly jobless claims and GDP data. Tesla stock reversed lower on earnings.

Which stocks could be helped or hurt the most by DeepSeek? Seeking Alpha analysts Joe Albano, Michael Del Monte and Harrison ...

As China's DeepSeek-R1 shakes up the AI landscape, India is racing to catch up. With IT Minister Ashwini Vaishnaw pushing for a homegrown AI model and Bhavish Aggarwal's Krutrim making headlines, ...

DeepSeek-R1, developed by a Chinese AI lab, is potentially highly competitive and shockingly cost-effective, and could be a ...

Tech leaders and their companies have reacted with admiration and insights after AI company DeepSeek launched its flagship large language model, R1. Just days after DeepSeek launched, the app ...

India’s IT Minister, Ashwini Vaishnaw, has pointed to the Chinese startup DeepSeek as an example of how AI development can be achieved at a lower cost, drawing a comparison with India’s own AI ...